Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 75%
filed 2026-09-01
This 8-K discloses a change of servicer under Item 6.02 (Asset-Backed Securities). Effective September 1, 2026, C-IV Asset Management LLC replaced Greystone Servicing Company LLC as special servicer for the FIVE 2023-V1 securitization, acquiring substantially all assets of Greystone's special servicing division and assuming all duties and liabilities. The filing details C-IV AM's qualifications, ratings, and portfolio of approximately $20.7 billion in aggregate principal balance across 60 transactions. While this is a material operational change affecting the administration of mortgage-backed securities, it does not fit the specific named event types (it is not M&A, debt issuance, impairment, etc.) and is best classified as an operational event related to servicer transition.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-01
Item 6.02
This disclosure reports a change of special servicer for a mortgage-backed securitization pool under Item 6.02. Greystone Servicing Company LLC sold its special servicing division to C-IV Asset Management LLC, which assumed all duties and liabilities for approximately 60 transactions representing $20.7 billion in aggregate principal balance as of June 30, 2026. While the servicer change itself is administrative, the scale of the portfolio transfer (60 CMBS and other transactions, $20.7 billion in assets) and the operational continuity measures described (key employee retention, compliance procedures, business continuity planning) indicate this is a material operational event affecting the securitization's servicing infrastructure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-01
Item 8.01
The filing discloses that C-IV Asset Management LLC will assume the role of special servicer for specific mortgage loans (Sentinel Square II and Centers of High Point) within the FIVE 2023-V1 securitization effective September 1, 2026. This is an operational change in the servicing arrangement for material assets underlying the securitization, affecting how loan administration and REO property servicing will be handled. While not a traditional M&A transaction or governance change, this servicer transition is material to investors in the securitization as it affects the operational management of the underlying collateral.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-01
Item 6.02
This Item 6.02 discloses a change of servicer in a mortgage securitization: Greystone Servicing Company LLC sold substantially all assets of its special servicing division to C-IV Asset Management LLC on September 1, 2026, with C-IV AM assuming all duties and liabilities as special servicer. The filing includes extensive detail on C-IV AM's qualifications, ratings, portfolio size ($20.7 billion aggregate principal balance), and operational procedures. While this is a servicer transition in a securitized mortgage trust, it is fundamentally an operational/contractual change affecting the administration of the underlying loan portfolio rather than a financial event (debt issuance, impairment, etc.), governance matter (board/executive change), or legal dispute. The materiality stems from the scale of the portfolio transferred and the operational continuity implications for certificateholders.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-31
Item 8.01
Incyte has entered into a pricing agreement with CMS affecting access to Jakafi and Jakafi XR through state Medicaid programs and providing relief from future CMS pricing mandates (GUARD and GLOBE models). While the company states no material impact on 2026 guidance or future outlook, the agreement represents a material operational and strategic development affecting drug pricing, market access, and regulatory exposure for a major product line. This is a significant business arrangement that does not fit neatly into other categories but is clearly operational in nature.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
IRSA has signed a barter agreement for a 2,095 sqm lot with 7,483 sqm total saleable area as part of the "Ramblas del Plata" real estate development project, valued at approximately USD 6.7 million. This is a material operational/strategic transaction involving a significant real estate acquisition and development activity, but does not fit the specific categories of M&A (no change of control), debt issuance, or other defined event types. The transaction is material to investors as it represents a substantial capital commitment and project expansion for this real estate company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
EX-99.1
This exhibit announces positive initial assay results from a sampling program on stockpiles under a profit-share agreement with Red Eye Resources, indicating gold and silver grades (weighted average 2.83 g Au and 753.41 g Ag) that will inform processing decisions at Nicola's Merritt Mill. The disclosure is operational—it reports on exploration/sampling results and next steps (laboratory simulations)—rather than a discrete event like M&A, financing, or executive action. It is material because it provides technical data that could affect investor assessment of the company's near-term mill utilization and project economics.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
This exhibit announces a fundamental business transformation of Amber International Holding Ltd from "Amber Premium" to "AMBR," a rebranding and strategic pivot to an agentic AI company focused on building specialized AI agents for finance, enterprise, and growth. The company is launching flagship products (Ambre for personal finance and MIA for marketing). This is a material operational and strategic business event—a significant pivot in business model and market positioning—that does not fit the specific named event types but clearly falls within the operational domain as a major strategic transformation and product launch.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99
This press release announces IperionX's receipt of a second U.S. Army task order (Task Order 2) under its existing SBIR Phase III contract, with US$11.5 million currently obligated and up to US$25.4 million potential value. The disclosure describes a material operational and strategic milestone—expansion of the company's titanium powder-to-part manufacturing capacity at its Virginia facility, including continuous HSPT™ furnace development, in-house fastener finishing equipment, and industrial-scale dehydrogenation furnaces. While this is a government contract award (operational/strategic), it does not fit the specific categories of M&A activity, debt issuance, equity dilution, or other named event types; it is a material contract/partnership milestone that would affect a reasonable investor's assessment of the company's growth trajectory and defense-sector positioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
BridgeBio announced a voluntary agreement with the U.S. government to expand Medicaid access to its marketed medicine (Attruby) and lower drug costs, with the company expecting to avoid future pricing mandates. This is a material strategic and regulatory agreement affecting the company's commercial operations and pricing framework, but it does not fit neatly into the specific event categories (not M&A, not a restatement, not a covenant breach, not litigation). The agreement is operational and regulatory in nature, affecting market access and pricing policy going forward.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
Alvotech announced FDA acceptance for review of a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio for subcutaneous administration. This is a material regulatory milestone in the company's biosimilar development pipeline—FDA acceptance for review is a significant step toward potential market approval. While not a discrete M&A event, covenant breach, or other specifically-named category, this regulatory advancement is clearly operational and strategic, affecting investor assessment of the company's pipeline progress and commercial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
This press release announces the signing of a binding offtake agreement with LG Energy Solution for 8,000 metric tonnes per year of battery-quality lithium carbonate over 10 years for the South West Arkansas Project. Combined with the previously announced Trafigura agreement, this secures approximately 90% of the targeted offtake volume and is explicitly described as "another major milestone in the development of the SWA Project" and critical to supporting project financing and a Final Investment Decision. While this is a material commercial contract that advances the project toward FID and construction, it does not fit the specific categories of M&A activity, debt issuance, or other named event types—it is a strategic operational/commercial milestone for a development-stage project.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
B2Gold reports a fatal workplace incident at its Masbate Gold Project in the Philippines on August 28, 2026, involving a pipe burst during scheduled maintenance at the Water Treatment Plant. While the company states mining and processing activities continue uninterrupted, a fatality at an operating mine is a material operational and safety event that would affect a reasonable investor's assessment of the company's operational risk, safety culture, and potential regulatory or legal consequences. This does not fit the specific categories of workforce_reduction (which addresses planned restructuring), material_litigation (no lawsuit disclosed), or legal_other (no regulatory action yet disclosed), but is clearly a material operational incident requiring disclosure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
Honda and Nissan have concluded a joint development agreement to standardize electronic control units (ECUs) and software for next-generation software-defined vehicles (SDVs), with planned application from fiscal year 2029 onward. This is a material strategic partnership in a core technology domain (vehicle software and electrification) that will affect Honda's product development, R&D efficiency, and competitive positioning, though the registrant notes no anticipated material impact on consolidated financial results for FY2027. The event is operational and strategic rather than fitting a discrete category like M&A, debt issuance, or executive change.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
Karyopharm announced submission of a supplemental New Drug Application (sNDA) to the FDA seeking Accelerated Approval for XPOVIO in combination with ruxolitinib for myelofibrosis, with a request for Priority Review. This is a material regulatory and operational milestone in the drug development and commercialization process that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects. While the filing does not fit neatly into predefined categories like earnings, M&A, or litigation, it represents a significant operational/strategic development in the company's core business of bringing therapeutics to market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
The 6-K discloses that MGP, an indirect subsidiary, has submitted a renewal application to the Hong Kong Stock Exchange for a potential listing on the Main Board following the lapse of its original application. The filing incorporates by reference MGP's audited consolidated financial statements for the year ended December 31, 2025, and the six months ended June 30, 2026. This is a material operational and strategic development involving a potential capital markets transaction by a subsidiary, though the outcome remains uncertain pending regulatory approval and market conditions.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
PMV Pharmaceuticals announced updated interim Phase 2 clinical trial data for rezatapopt in ovarian cancer, showing a 46% overall response rate with a 10.0-month median duration of response, and disclosed FDA feedback supporting an NDA submission strategy for accelerated approval planned in Q1 2027. This is a material clinical and regulatory milestone for a precision oncology company's lead product candidate, but does not fit the specific event types (earnings, M&A, impairment, etc.); it is best classified as an operational milestone—the advancement of a key clinical program toward regulatory approval.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
This press release announces completion of patient enrollment in the IMPACT clinical trial for Alpha DaRT in pancreatic cancer, with enrollment expanded three times from 12 to 48 patients. The disclosure highlights a significant operational and clinical milestone — successful rapid enrollment in a pivotal pilot study that will inform design of a planned pivotal trial — which is material to investors assessing the company's clinical development progress and commercial prospects for its lead therapeutic candidate. The event does not fit a discrete named category (not an earnings release, M&A activity, executive change, or other specific event type), but is clearly a material operational/clinical development milestone.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-31
Item 8.01
Cadrenal announced positive feedback from an FDA Type D meeting on July 28, 2026, regarding alignment on the primary endpoint definition and Statistical Analysis Plan for the Phase 3 registrational study of CAD-1005 for heparin-induced thrombocytopenia. FDA agreement on trial design elements represents a material regulatory milestone that advances the company's path to potential commercialization of this first-in-class therapeutic.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
The filing discloses completion of Phase 2 development of the Company's Catch-Up agentic AI video platform in collaboration with AWS and Caylent, with AWS providing $125,000 in project funding. This is a material operational milestone—the successful completion of a contingent development project with a strategic partner and receipt of associated funding—but does not fit neatly into specific categories like debt issuance, M&A, or earnings release. It is clearly operational/strategic in nature and material to investors evaluating the Company's product development progress and AI strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
EX-99.1
Turbogen announced approval and commencement of trading of its ordinary shares on the Nasdaq Capital Market on August 31, 2026, while maintaining its existing listing on the Tel Aviv Stock Exchange. This is a material operational and strategic milestone — a secondary listing on a major U.S. exchange — that expands the company's capital market access and investor base. While not a discrete M&A event, debt issuance, or governance action, it is a significant operational/strategic development that would affect a reasonable investor's assessment of the company's profile, liquidity, and growth prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
The Sponsor has expanded the Teucrium Wheat Fund's investment discretion to include alternative wheat futures contracts (KC HRW and MGEX HRS) in addition to its benchmark component contracts, effective immediately. This is a material operational and investment policy change that affects how the Fund will manage its portfolio and could impact NAV correlation with its benchmark, as explicitly disclosed. The filing of a prospectus supplement under Rule 424(b)(3) confirms the materiality of this strategic shift in the Fund's investment approach.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-31
Item 8.01
The disclosure reports that the 7RCC Spot Bitcoin and Carbon Credit Futures ETF has reached the minimum threshold of 50,000 outstanding shares, triggering the Sponsor's right to reject redemption orders and creating operational constraints on the Fund. While this is a fund-specific operational matter rather than a traditional corporate event, it materially affects investor liquidity and trading conditions by reducing secondary market liquidity and potentially widening bid-ask spreads, which would affect a reasonable investor's assessment of the Fund's tradability and value realization.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
The filing discloses Nova Minerals' CEO attendance at a U.S. Department of Energy roundtable to brief officials on the company's progress toward establishing a domestic antimony supply chain from its Estelle project in Alaska. The press release highlights government support (including a $43.4 million Department of War award), Secretary of Energy endorsement of the project's strategic importance, and planned phase 1 production in 2027. This is a material operational and strategic milestone—a government-backed critical minerals initiative with explicit DoE/DoW backing—but does not fit the specific categories of M&A, earnings, executive changes, or other named event types. It is clearly operational/strategic in nature and material to investors assessing the company's project development and government support.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
EX-99.1
PowerBank announces a Fee for Service Development Agreement with 1001634281 Ontario Inc. to develop battery energy storage projects for submission to IESO's LT2(c-2) procurement, with potential to serve as EPC provider if a contract is granted. This is a material strategic partnership and market opportunity in Ontario's energy storage sector. The exhibit also discloses a debt settlement involving issuance of approximately 1.3 million common shares at $0.63 per share to settle $817,332 of legal fees, which is a dilutive capital event. The primary focus is the operational development agreement; the debt settlement is secondary but material as a dilutive issuance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-31
The filing discloses an operational update on the Company's digital asset holdings and treasury strategy via press release under Item 7.01 (Regulation FD Disclosure). The press release announces Bitmine's ETH holdings reaching 5.90 million tokens (4.9% of total ETH supply), total crypto and cash holdings of $15.6 billion, staking operations generating projected $340 million annualized revenues, and progress toward the "Alchemy of 5%" goal. While this is a strategic business update regarding the Company's core digital asset accumulation and staking operations, it does not fit neatly into earnings_release (no quarterly/annual financial results), financial_other (no capital event, impairment, or accounting matter), or other specific categories. The disclosure is material to investors assessing the Company's operational progress and asset position.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
EX-99.1
This press release announces a material operational milestone: the K-29 well at Kruh Block has reached total depth (3,378 feet) and testing operations are in preparation. The disclosure describes progress on a core exploration and drilling program in Indonesia, which is central to IEC's business strategy. While not fitting a discrete event category like M&A or impairment, the well-drilling milestone and transition to testing operations represent a material operational development that would affect a reasonable investor's assessment of the company's exploration progress and near-term operational trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Verde Resources announced entry into a non-binding Memorandum of Understanding with Highway International to collaborate on deployment, validation, and commercialization of its engineered biochar carbon platform in Singapore. The MoU establishes a strategic framework for a pilot project with Singapore's Land Transport Authority and contemplates an exclusive licensing arrangement. This is a material operational/strategic partnership that positions Singapore as a regional launchpad for the company's technology commercialization and Asia-Pacific expansion, though the MoU is non-binding and subject to successful pilot validation and definitive agreement execution.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
EX-99.1
The exhibit announces the commencement of trading on Nasdaq as a dual-listed company, with the Nasdaq registration statement becoming effective on August 31, 2026, and shares trading under symbol "GIXI" beginning September 1, 2026. This is a material operational and strategic milestone — a listing on a major U.S. exchange — that would significantly affect investor access and the company's capital-raising profile, but it does not fit the specific event categories (it is not M&A, governance, financial obligation, or litigation). The transition to U.S. reporting standards under Israeli Securities Law Chapter E'3 is also a material operational change.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
Strive announced a bitcoin purchase of 1,800 BTC at approximately $79,431 per bitcoin during August 24-28, 2026, along with updates to its treasury holdings and share counts. This represents a material operational/strategic decision to deploy capital into digital assets as part of the company's bitcoin treasury strategy, which is referenced in the forward-looking statements as a key component of the merger transaction with Semler Scientific. While the disclosure is primarily informational (treasury position updates), the bitcoin acquisition itself constitutes a material capital deployment decision that would affect investor assessment of the company's strategic direction and financial position.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
This announcement discloses positive Phase III trial results for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China. The SANOVO trial demonstrated statistically significant progression-free survival benefit and encouraging overall survival results. This is a material clinical development milestone for a co-developed product that extends the therapeutic indication into the first-line setting, representing a significant operational and commercial advancement for the company's pipeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
Frontier entered into a direct lease agreement with AerCap Holdings N.V. for 10 A321neo aircraft with deliveries expected in Q4 2026 and Q1 2027, enhancing fleet capacity and operational flexibility.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-31
Item 7.01
The press release discloses Endovia's response to federal marijuana rescheduling developments (DEA support for Schedule III transfer), advancement of its CannEpil® FDA submission strategy, and plans to expand its cannabinoid-based pipeline through licensing and acquisition opportunities. While the filing touches on regulatory developments and product advancement, the core disclosure is operational and strategic—the company's positioning within an evolving regulatory environment and its pipeline expansion plans. This does not fit neatly into specific categories like `debt_issuance`, `ma_activity` (no deal announced), or `earnings_release`, making `operational_other` the most appropriate classification for a material strategic and business development disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-31
Item 8.01
Castellum announced a $32.8 million contract modification to its existing NAVAIR PMA-290 Special Missions contract, increasing the total ceiling to $136.2 million. This is a material operational and strategic event—a significant expansion of an existing government contract that the company describes as "the largest prime contract win in Castellum's history." The modification expands scope across multiple intelligence, surveillance, reconnaissance, and targeting programs and demonstrates customer confidence in performance. While this is a positive business development, it does not fit the specific categories of M&A activity, debt issuance, or other named financial events; it is best classified as a material operational/strategic milestone.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-28
Item 8.01
Quoin announced positive interim clinical trial results from the Phase 2/3 study CL-QRX003-004 of QRX003 for Netherton Syndrome, with the primary endpoint met with statistical significance (p=0.0087 vs. α=0.0215) in 4 of 6 participants. This material clinical milestone represents a significant development in the company's late-stage specialty pharmaceutical pipeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-28
Item 8.01
Roivant disclosed FDA approval and commercial launch of LISRAYA (brepocitinib) for dermatomyositis treatment on August 28, 2026. This is a material regulatory milestone and product commercialization event—the company's first approved drug product—but does not fit the specific taxonomy categories. While it is clearly operational/strategic in nature (product approval and launch), it is not a traditional M&A activity, workforce reduction, or material contract. The disclosure centers on regulatory approval achievement and immediate commercial availability, making it a significant operational milestone for the company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-28
EX-99.1
This press release announces completion of the first underground blast at Anfield's Velvet-Wood uranium and vanadium mine in nearly 40 years, along with progress on rehabilitation work (decline rehabilitation, water treatment plant construction, and dewatering infrastructure). While this represents a significant operational milestone in advancing the project toward production, it does not fit the specific event-type categories (not an earnings release, M&A activity, impairment, litigation, or other named events). The disclosure is material because it demonstrates concrete progress on a key asset in the company's hub-and-spoke strategy and signals movement toward the next development phase, which would affect a reasonable investor's assessment of the company's operational trajectory and near-term production prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-28
EX-99.1
This exhibit is a corporate presentation disclosing Aura Minerals' operational and strategic portfolio overview, including production guidance (340k–390k GEO in 2026), asset details, cost metrics, capital investment plans, and development milestones for multiple mining projects (Borborema, Era Dorada, Matupá, MSG). While it contains forward-looking statements and operational metrics typical of investor presentations, it does not constitute a discrete event (such as M&A, executive change, or debt issuance) nor a periodic financial report with audited statements. The presentation highlights operational improvements, capacity expansions, and project construction progress—material operational and strategic disclosures that would affect a reasonable investor's assessment of the company's growth trajectory and execution capability.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-28
Item 8.01
Cytokinetics announced positive Phase 3 clinical trial results for aficamten (ACACIA-HCM) in non-obstructive hypertrophic cardiomyopathy, with plans to submit a supplemental New Drug Application to the FDA in Q4 2026. While this is a significant clinical and regulatory milestone for the company's pipeline, it does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure centers on a material clinical development and regulatory milestone that would affect investor assessment of the company's prospects, making it a material operational/strategic event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-28
EX-99.1
This press release announces SuperX's receipt of a 128-unit B300 AI server purchase order from Ezisight Australia, marking the company's "official entry into the Australian market" and described as "a substantive business breakthrough" and "key milestone in the Company's Asia-Pacific business expansion." While this is a material commercial contract and market-entry event, it does not fit the specific operational categories (workforce reduction, restructuring) or other defined event types. The disclosure is clearly operational and strategic in nature—a significant customer order and geographic expansion—making it material to a reasonable investor's assessment of the company's growth trajectory and market presence.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-28
EX-99.1
Xanadu announced a definitive agreement with the Government of Canada for CAD $195 million in funding through the Strategic Response Fund to establish advanced manufacturing facilities for photonic quantum computing components in Toronto. The 158,000-square-foot facility, named Inception, represents a landmark strategic investment in quantum manufacturing capability and is supported by Project OPTIMISM.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-28
EX-99.1
Pacific Booker announces engagement of Tetra Tech to complete a Pre-Feasibility Study (PFS) for its Morrison Copper-Gold Project, with an updated Mineral Resource Estimate expected in one month and the full PFS in Q1 2027. This represents a material operational milestone in project advancement—a significant step toward potential future development of the company's core asset. The secondary disclosure of stock options exercise proceeds ($2.07 million) used to repay director loans and working capital is routine capital management and does not alter the primary operational event classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-28
This is a press release announcing U.S. FDA approval of MIMRYLO™ (rusfertide), a first-in-class hepcidin mimetic for treating polycythemia vera. The disclosure is a material regulatory milestone and product approval event. While it is not a discrete M&A transaction, earnings release, or executive change, it represents a significant operational and commercial milestone—the successful regulatory approval of a novel therapeutic product that Takeda has exclusive global development and commercialization rights for. The filing explicitly states "This approval does not result in any changes to Takeda's consolidated financial forecast for the fiscal year ending March 31, 2027," confirming this is a regulatory event rather than a financial restatement or guidance change. The event is material to investors assessing Takeda's pipeline, competitive position, and future revenue potential in oncology/rare diseases.
View raw filing on EDGAR →
8-K
Operational Other
confidence 65%
filed 2026-08-28
Item 1.01
The 8-K discloses a Product Purchase Agreement dated August 25, 2026, between Boxabl Inc. and LC Vegas Acquisitions, LLC, with a First Amendment also executed the same date. While Item 9.01 exhibits are shown, the Item 1.01 reference suggests this involves a material transaction or contract. The redaction of portions under Reg S-K 601(b)(10) indicates confidential commercial terms. This appears to be a material commercial contract or product sale arrangement, which qualifies as an operational event, though the specific nature (whether a one-time sale, ongoing supply arrangement, or other transaction) cannot be fully determined from the exhibits section alone.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-28
The filing discloses FingerMotion's strategic pivot to become an owner-operator of behind-the-meter AI data center capacity in North America, executed through a partnership with BlueFlare Energy Solutions and a 9.9% equity investment in Lyken.AI (closed August 17, 2026). This represents a material operational and strategic business transformation from the company's existing mobile payment and telecommunications operations in China. While the filing also mentions the Lyken.AI acquisition, the primary focus is the strategic business plan and operational repositioning rather than the acquisition itself as a discrete M&A event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-28
Item 8.01
The filing discloses a 1-for-8 reverse stock split announced on August 26, 2026, along with operational and financial updates including margin expansion (6.1% to 29.1%), a $54.6M HHS contract award, debt reduction, and multi-year revenue visibility. While the reverse split itself is a capital structure event, the press release centers on operational and strategic achievements (acquisitions, margin improvement, contracted revenue) rather than a discrete financial obligation or governance action. This is best classified as an operational/strategic disclosure that does not fit the specific categories of debt issuance, dividend distribution, or other named types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-28
EX-99.1
This press release announces NMPA (China National Medical Products Administration) conditional approval of ATLED® (fanregratinib) for treating FGFR2-altered intrahepatic cholangiocarcinoma. This is a material regulatory milestone and product approval event that does not fit the specific `earnings_release` category (no financial results disclosed) nor other named event types. The approval represents a significant operational and commercial achievement for the company's drug development pipeline, supported by Phase II trial data meeting primary endpoints (42.5% ORR). This would materially affect a reasonable investor's assessment of the company's commercial prospects and pipeline value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-28
EX-99.1
This press release announces a maiden mineral resource estimate (MRE) for Caledonia's Motapa property in Zimbabwe—379,000 oz measured and indicated plus 131,000 oz inferred gold. The disclosure is a significant operational and strategic milestone demonstrating exploration success and value creation ($40.45 per ounce discovery cost), with potential synergies to the adjacent Bilboes Gold Project under development. While not a discrete M&A transaction, earnings release, or other named event type, this is a material operational disclosure affecting investor assessment of the company's asset base and long-term production potential.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-28
EX-99.1
This press release announces a 22% increase in measured and indicated mineral resources at Blanket Mine to 2.178 million ounces of gold, plus a maiden surface mineral resource estimate. While the disclosure includes exploration results and resource estimates (operational/strategic matters), it does not fit the discrete event categories of earnings_release, ma_activity, or material_impairment. The resource upgrade and new surface discovery represent material operational developments affecting the company's long-term production profile and mine-life extension potential, warranting classification as a material operational event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-28
EX-99.1
Scorpio Gold announces approval to list American Depositary Shares (ADSs) on NASDAQ under symbol "SGLD" effective September 1, 2026, with concurrent ticker symbol change on TSX Venture Exchange. This is a material capital-markets and strategic milestone that enhances investor access and liquidity without requiring a share consolidation, though it does not fit the specific categories of M&A activity, debt issuance, or other named event types. The listing is a significant operational and strategic development for the company's growth trajectory.
View raw filing on EDGAR →